In summary, our research indicates that OPC may serve as a potential therapeutic candidate by targeting and regulating C2 NR4A1+ MSCs in osteopenia, thereby playing a role in the prevention and treatment of OP. This evidence concerns the gene NR4A1 and Osteopenia.